01 March 2021


("IXICO" or the "Company")

Conference attendance and presentations

IXICO virtually attends AD/PD 2021 Conference

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience , announces it will be presenting at the upcoming virtual AD/PD 2021 conference taking place virtually on 9-14 March 2021. AD/PD 2021, the 15th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, is one of the most prestigious in the year and IXICO welcomes the opportunity to present.

The following presentation and poster presentations will be made across the week:

-- Michael Reinwald, PhD, Associate Research Engineer at IXICO plc, will give a pre-recorded oral presentation, titled: " A deep-learning based framework for brain-atrophy measurement"

-- Jack Weatheritt, PhD, Senior Research Engineer at IXICO plc, will present the poster: "Automatic segmentation using deep learning for the hippocampus"

   --    Luis Peraza, PhD, Research Engineer at IXICO plc, will present two posters: 

1) "An adaptive step detection algorithm for waist-worn wearable devices: a feasibility study in older adults"

2) "Added value of wearable sensors for fall risk assessment in an older adult group"

The conference attracts international medical and scientific professionals worldwide to focus on the mechanisms of disease, prevention and therapy within the neurodegenerative disease space. More information on the conference can be found here: Welcome Message - AD/PD(TM) 2021 | March 9 - 14, 2021 | Virtual Conference (kenes.com)

Robin Wolz, Chief Scientific Officer at IXICO, commented: "We are excited about the opportunity to provide an update on various R&D activities at the AD/PD conference. Deep learning approaches in combination with well curated, high-quality data enable us to develop tools that can extract clinically meaningful insights that were previously not detectable and at a processing speed previously unthinkable. We look forward to sharing an update on how this technology impacts our ability to interpret both imaging and wearables data."

The video presentation and related posters will be available on the Company's website after the event has concluded, here: Webinars >> IXICO and Publications >> IXICO .

For further information please contact:

 IXICO plc                                      +44 (0)20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                              +44 (0)20 7397 8900 
 Giles Balleny / Max Gould (Corporate 
 Michael F Johnson / Russell Kerr 
 Walbrook PR Ltd                                +44 (0)20 7933 8780 
 Paul McManus / Lianne Cawthorne               IXICO@walbrookpr.com 
 Alice Woodings 


IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

   More information is available on   www.IXICO.com   and follow us on Twitter @IxicOplc 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

March 01, 2021 02:00 ET (07:00 GMT)